Ensysce Biosciences, Inc.
ENSC
$0.47
$0.000.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -91.80% | -72.93% | -27.40% | -38.44% | 41.64% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | -100.00% |
| Total Other Non-Cash Items | 221.87% | 466.20% | 512.43% | -37.39% | -50.27% |
| Change in Net Operating Assets | 25,898.98% | 61.83% | 278.00% | 221.41% | 101.26% |
| Cash from Operations | -42.86% | -65.47% | -4.05% | 17.52% | 36.64% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 12.59% | 12.44% | 74.78% | 77.09% | 74.50% |
| Issuance of Common Stock | -38.01% | -36.01% | -10.50% | -10.67% | 69.56% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -112.31% | -35.25% | -80.30% | -77.16% | -3.89% |
| Cash from Financing | 1.05% | 36.09% | -11.57% | -58.25% | 5.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -231.38% | -555.80% | -66.02% | -192.24% | 141.93% |